Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests
Presentation Shows MammaPrint Can Accurately Stratify Recurrence Risk up to Read More
Agendia Co-Founder Awarded EU Prize for Women Innovators
Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Read More
Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence
Scientific Poster and Symposium at Miami Breast Cancer Conference Demonstrate Value Read More
Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 27, 2014– A Read More
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Read More
Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference
Next-Generation Genomic Tests Determine Molecular Subtypes and Risk of Recurrence, Read More
Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDs’ Attention Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
‘High Risk’ Patients with Unusual Hormone Receptors May Be Undertreated Read More
